Takeaway
Tumor histologies and molecular markers are prognostic factors effecting overall survival (OS) and intracranial (IC) progression in surgically treated brain metastases (BM).
Why this matters
Known prognostic and survival factors in BM patients will allow for better clinical decision making to balance disease control and quality of life.